MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
MADRIGAL PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$447.09−2.65 (-0.59%)
Close on Oct 19, 2026
- Market cap
- $13.03B
- P/E (TTM)
- –
- Dividend yield
- –
Madrigal Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Madrigal Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $10.33B | $197.05M |
| Enterprise Value | $9.83B | $106.56M |
| PS Ratio | 8.05 | 3.93 |
| PB Ratio | 19.72 | 2.14 |
| P/TBV Ratio | 20.00 | 2.46 |
Enterprise value
| Measure | Madrigal Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 7.66 | 2.69 |
Income (trailing twelve months)
| Measure | Madrigal Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $1.28B | $57.94M |
| Operating Income | -$322.62M | -$21.44M |
| Net Income | -$325.10M | -$22.46M |
| EBITDA | -$321.10M | -$16.91M |
| EPS (Diluted) | -$11.28 | -$0.83 |
Margins
| Measure | Madrigal Pharmaceuticals | Industry median |
|---|---|---|
| Operating Margin | -25.1% | -44.5% |
| Profit Margin | -25.3% | -39.2% |
| EBITDA Margin | -25.0% | -31.3% |
| FCF Margin | -16.1% | -8.85% |
Returns
| Measure | Madrigal Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | -53.3% | -53.1% |
| Return on Assets (ROA) | -28.8% | -41.0% |
| Return on Invested Capital (ROIC) | -1338.0% | -32.0% |
| Return on Capital Employed (ROCE) | -37.1% | -37.8% |
Growth
| Measure | Madrigal Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 149.0% | 6.01% |
Balance sheet
| Measure | Madrigal Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $838.75M | $62.42M |
| Total Debt | $340.79M | $120.13M |
| Net Cash (Debt) | $497.96M | $15.68M |
| Net Cash Per Share | $21.55 | $0.65 |
| Equity (Book Value) | $523.72M | $48.79M |
| Book Value Per Share | $22.67 | $1.36 |
| Tangible Book Value | $516.54M | $23.06M |
| Working Capital | $824.98M | $75.77M |
Financial position
| Measure | Madrigal Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 3.20 | 3.30 |
| Quick Ratio | 2.76 | 2.39 |
| Debt / Equity | 0.65 | 0.51 |
| Interest Coverage | -10.24 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Madrigal Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | -$197.72M | -$12.35M |
| Capital Expenditures | -$8.57M | -$1.06M |
| Free Cash Flow | -$206.29M | -$20.28M |
| FCF Per Share | -$8.93 | -$0.41 |
Efficiency
| Measure | Madrigal Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 1.14 | 0.38 |
| Revenue Per Employee | $1.40M | $398.96K |
| Profits Per Employee | -$355.30K | -$732.08K |
| Employee Count | 915 | 73 |
Dividends and yields
| Measure | Madrigal Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -3.15% | -21.2% |
| FCF Yield | -2.00% | -7.64% |
Shares
| Measure | Madrigal Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 23,104,100 | 59,128,900 |
| Shares Change (YoY) | -5.75% | 11.1% |
| Shares Change (QoQ) | 0.23% | 0.54% |
| Float | 17,486,500 | 48,744,500 |
| Shares Held by Insiders | 24.3% | 11.8% |
| Shares Held by Institutions | 102.6% | 59.4% |
Scores
| Measure | Madrigal Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | 7.05 | 0.10 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Madrigal Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.